Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26657290
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26657290
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Oncotarget
2016 ; 7
(3
): 3548-58
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in
non-small cell lung cancer cells
#MMPMID26657290
Li H
; Hu J
; Wu S
; Wang L
; Cao X
; Zhang X
; Dai B
; Cao M
; Shao R
; Zhang R
; Majidi M
; Ji L
; Heymach JV
; Wang M
; Pan S
; Minna J
; Mehran RJ
; Swisher SG
; Roth JA
; Fang B
Oncotarget
2016[Jan]; 7
(3
): 3548-58
PMID26657290
show ga
Auranofin, a gold complex that has been used to treat rheumatoid arthritis in
clinics and has documented pharmacokinetic and safety profiles in humans, has
recently been investigated for its anticancer activity in leukemia and some solid
cancers. However, auranofin's single agent activity in lung cancer is not well
characterized. To determine whether auranofin has single agent activity in lung
cancer, we evaluated auranofin's activity in a panel of 10 non-small cell lung
cancer (NSCLC) cell lines. Cell viability analysis revealed that auranofin
induced growth inhibition in a subset of NSCLC cell lines with a half maximal
inhibitory concentration (IC50) below 1.0 ?M. Treatment with auranofin elicited
apoptosis and necroptosis in auranofin-sensitive cell lines. Moreover, the
susceptibility of NSCLC cells to auranofin was inversely correlated with TXNRD1
expression in the cells. Transient transfection of the TXNRD1-expressing plasmid
in auranofin-sensitive Calu3 cells resulted in partial resistance, indicating
that high TXNRD level is one of causal factors for resistance to auranofin.
Further mechanistic characterization with proteomic analysis revealed that
auranofin inhibits expression and/or phosphorylation of multiple key nodes in the
PI3K/AKT/mTOR pathway, including S6, 4EBP1, Rictor, p70S6K, mTOR, TSC2, AKT and
GSK3. Ectopic expression of TXNRD1 partially reversed auranofin-mediated
PI3K/AKT/mTOR inhibition, suggesting that TXNRD1 may participate in the
regulation of PI3K/AKT/mTOR pathway. Administration of auranofin to mice with
xenograft tumors derived from NSCLC cells significantly suppressed tumor growth
without inducing obvious toxic effects. Our results demonstrated feasibility of
repurposing auranofin for treatment of lung cancer.
|Animals
[MESH]
|Antirheumatic Agents/pharmacology
[MESH]
|Apoptosis/drug effects
[MESH]
|Auranofin/*pharmacology
[MESH]
|Blotting, Western
[MESH]
|Carcinoma, Non-Small-Cell Lung/metabolism/pathology/*prevention & control
[MESH]
|Cell Proliferation/drug effects
[MESH]
|Flow Cytometry
[MESH]
|Humans
[MESH]
|Lung Neoplasms/metabolism/pathology/*prevention & control
[MESH]